- Innate Pharma SA IPHA stock closed almost 14% higher on Thursday after the Company disclosed two upcoming presentations scheduled at ESMO 2021 Virtual Congress.
- The presentations include a late-breaker abstract on a Phase 2 trial highlighting the progression-free survival data for monalizumab combination therapy in non-small cell lung cancer (NSCLC).
- Continuing yesterday's gain, Innate Pharma stock is rising in the market trading as SVB Leerink has upgraded the stock to Outperform from Market Perform.
- Analyst Daina Graybosch says that a positive outcome would de-risk a vast opportunity for monalizumab and transform the narrative around the Company.
- AstraZeneca Plc AZN owns full oncology rights for monalizumab, is scheduled to make the presentation on the clinical trial.
- Read Next: Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints.
- Price Action: IPHA stock is up 22.40% at $5.12 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
